Effect of L-Carnitine (LC) and conjugated linoleic acid (CLA) supplements on hemoglobin levels in CKD patients

Effect of L-Carnitine (LC) and conjugated linoleic acid (CLA) supplements on hemoglobin levels in CKD patients with different haptoglubin genotype

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201503055144N7

Enrollment

Registered

2017-05-18

Start date

2015-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal failure. N18.2-N18.4

Interventions

Given 1000 milligram L-carnitine and 2400 milligram CLA per day for 30 days.

Treatment - Drugs

Given 1000 milligram L-carnitine and 2400 milligram CLA per day for 30 days

Eligibility

Sex/Gender

Male

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Male patients with anemic chronic kidney disease over 20 years old Exclusion criteria: Women; Male patients with other disease such as cardiovascular; lung disease; diabetes

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Anemia. Timepoint: At the end of study. Method of measurement: Measurement of hemoglobin and hematocrit.	—

Secondary

Measure	Time frame
Height. Timepoint: At the beginning of intervention. Method of measurement: Stadiometers.;L-Carnitine. Timepoint: One month. Method of measurement: Milligram.;Conjugated linoleic acid. Timepoint: One month. Method of measurement: Milligram.;Weight. Timepoint: At the beginning and end of intervention. Method of measurement: Digital scales.;Hemoglobin. Timepoint: At the beginning and end of intervention. Method of measurement: Cell counter.;Hematocrit. Timepoint: At the beginning and end of intervention. Method of measurement: Cell counter.;Serum iron. Timepoint: At the beginning and end of intervention. Method of measurement: Photometric method.;Serum Ferritin. Timepoint: At the beginning and end of intervention. Method of measurement: Chemiluminescence immunoassay.;HsCRP. Timepoint: At the beginning and end of intervention. Method of measurement: Immunometric method.;Srum TIBC. Timepoint: At the beginning and end of intervention. Method of measurement: Photometric method.;Serum interleukin-6. Timepoint: At the beginning and the end of intervention. Method of measurement: ELISA.;DNA extraction. Timepoint: At the end of intervention. Method of measurement: Cinnagen kit.;Haptoglobin genotype. Timepoint: At the end of intervention. Method of measurement: PCR method.	—

Measure

Time frame

Height. Timepoint: At the beginning of intervention. Method of measurement: Stadiometers.;L-Carnitine. Timepoint: One month. Method of measurement: Milligram.;Conjugated linoleic acid. Timepoint: One month. Method of measurement: Milligram.;Weight. Timepoint: At the beginning and end of intervention. Method of measurement: Digital scales.;Hemoglobin. Timepoint: At the beginning and end of intervention. Method of measurement: Cell counter.;Hematocrit. Timepoint: At the beginning and end of intervention. Method of measurement: Cell counter.;Serum iron. Timepoint: At the beginning and end of intervention. Method of measurement: Photometric method.;Serum Ferritin. Timepoint: At the beginning and end of intervention. Method of measurement: Chemiluminescence immunoassay.;HsCRP. Timepoint: At the beginning and end of intervention. Method of measurement: Immunometric method.;Srum TIBC. Timepoint: At the beginning and end of intervention. Method of measurement: Photometric method.;Serum interleukin-6. Timepoint: At the beginning and the end of intervention. Method of measurement: ELISA.;DNA extraction. Timepoint: At the end of intervention. Method of measurement: Cinnagen kit.;Haptoglobin genotype. Timepoint: At the end of intervention. Method of measurement: PCR method.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Nemati

Ardabil University of Medical Sciences

ali.nemati@arums.ac.ir+98 45 3351 0052

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026